ArticleMedical physics2026
A constraint-normalized robustness index for HDR brachytherapy.
Article in Medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGeometric uncertainties in high-dose-rate brachytherapy, including applicator displacement, catheter deflection, and interstitial needle spread, produce dose deviations that are patient and plan specific. Unlike external beam radiotherapy, where robustness evaluation frameworks are increasingly standardized, high dose rate brachytherapy lacks a normalized aggregate metric for quantifying plan sensitivity to geometric perturbations. PURPOSE: To define a bounded, dimensionless robustness index for per-fraction evaluation of high dose rate brachytherapy plans that is normalized to clinically meaningful dose-limit constraints, incorporates dose-dependent penalty sensitivity, and provides both a full-scenario severity measure and a dose-threshold-filtered variant.
methodsGeometric perturbation scenarios (translations, rotations, radial expansion/contraction, catheter deflection, and combined modes) are applied to source dwell positions. For each organ at risk, a convex-transformed, constraint-normalized penalty quantifies the fraction of the remaining margin to the dose-limit constraint consumed per scenario. For target volumes, a prescription-normalized piecewise penalty captures under-coverage and excessive dose escalation. The Robustness Index is defined as one minus the mean scenario penalty, yielding a value in [0,1].
resultsThe framework produces structure-independent, interpretable indices where a Robustness Index
conclusionsThe proposed robustness index provides a standardized, clinically anchored metric for high dose rate brachytherapy plan evaluation under geometric uncertainty, complementing existing dose volume histogram based reporting with a single interpretable number per structure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.